摘要
目的研究鼓室注射甲基泼尼松龙(MP)、利多卡因联合阈值声音调节疗法治疗特发性耳鸣的临床疗效。方法将80例特发性耳鸣患者均分为A组(鼓室注射MP+利多卡因+阈值声音调节法治疗,n=40)与B组(阈值声音调节法治疗,n=40),2组均连续治疗1个月,1个月后,统计并比较2组的治疗效果。结果2组治疗后,耳鸣严重程度分级较治疗前显著改善(P<0.05);A组治疗有效率为80.00%,显著高于B组的57.50%(P<0.05);治疗后,2组心理适应程度得分均较同组治疗前显著降低(P<0.05),且A组治疗后,心理适应程度得分显著低于B组(P<0.05);治疗1个月后,2组血清细胞黏附因子-1(sVCAM-1)及血清一氧化氮(NO)水平均较同组治疗前显著下降(P<0.05),且A组血清sVCAM-1及NO水平显著低于B组(P<0.05)。A组不良反应发生率为12.50%,与B组的2.50%比较差异无统计学意义(P>0.05)。结论鼓室注射利多卡因、MP联合阈值声音疗法治疗特发性耳鸣疗效较好,能有效缓解患者的耳鸣,减轻其心理不适感,且用药安全。
Objective To investigate the effect of intratympanic injection of methylprednisolone(MP)and lidocaine combined with threshold sound conditioning therapy in the treatment of idiopathic tinnitus.Methods 80 patients with idiopathic tinnitus were divided into group A(intra tympanum injection of MP+lidocaine+threshold sound adjustment method,n=40)and group B(threshold sound adjustment method,n=40).Group A received intratympanic injection of MP and lidocaine combined with threshold sound conditioning therapy,while group B received threshold sound conditioning therapy only.Treatment in both groups were lasted for 1 month,then the clinical efficacy was compared between the 2 groups.Results After treatment,tinnitus severity grade was significantly improved in both group(P<0.05).The effective rate was 80.00%in group A,which was higher than 57.50%in group B(P<0.05).After treatment,the scores of psychological adaptation were decreased in both groups(P<0.05),and were lower in group A than in group B(P<0.05).The serum levels of soluble vascular cell adhesion molecule-1(sVCAM-1)and nitrie oxide(NO)at post-treatment 1 month were lower than those before treatment in both groups,and were lower in group A than in group B(P<0.05).The incidence of adverse reactions was 12.50%in group A and 2.50%in group B,with no statistic difference(P>0.05).Conclusion Intratympanic injection of methylprednisolone and lidocaine combined with threshold sound conditioning therapy can effectively and safely alleviate the patients tinnitus degree,and reduce their psychological discomfort for patients with idiopathic tinnitus.
作者
李伟
胡县
吴兴宇
LI Wei;HU Xian;WU Xingyu(Ezhou Central Hospital,Ezhou 436000,China)
出处
《西北药学杂志》
CAS
2022年第1期108-111,共4页
Northwest Pharmaceutical Journal
基金
湖北省卫生健康委科研项目(编号:WJ2015MB268)。
